Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia

References

• Hehlmann R, Hochhaus A, Baccarani M. Chronic myeloid leukaemia. Lancet 2007; 370:342-50; PMID:17662883; http://dx.doi.org/10.1016/S0140-6736(07)61165-9
   PubMed Web of Science ®Google Scholar
• Jabbour E, Mathisen MS, O'Brien S. Ten years of progress in chronic myelogenous leukemia. J Natl Compr Canc Netw 2012; 10:1049-53; PMID:22956803
   PubMed Web of Science ®Google Scholar
• Kimura S, Ando T, Kojima K. Ever-advancing chronic myeloid leukemia treatment. Int J Clin Oncol 2014; 19:3-9; PMID:24258348; http://dx.doi.org/10.1007/s10147-013-0641-7
   PubMed Web of Science ®Google Scholar
• Briscoe J, Therond PP. The mechanisms of Hedgehog signalling and its roles in development and disease. Nat Rev Mol Cell Biol 2013; 14:416-29; PMID:24258348; http://dx.doi.org/10.1038/nrm3598
   PubMed Web of Science ®Google Scholar
• Atwood SX, Chang AL, Oro AE. Hedgehog pathway inhibition and the race against tumor evolution. J Cell Biol 2012; 199:193-7; PMID:23071148; http://dx.doi.org/10.1083/jcb.201207140
   PubMedGoogle Scholar
• Scales SJ, de Sauvage FJ. Mechanisms of Hedgehog pathway activation in cancer and implications for therapy. Trends Pharmacol Sci 2009; 30:303-12; PMID:19443052; http://dx.doi.org/10.1016/j.tips.2009.03.007
   PubMed Web of Science ®Google Scholar
• Amakye D, Jagani Z, Dorsch M. Unraveling the therapeutic potential of the Hedgehog pathway in cancer. Nature Medicine 2013; 19:1410-22; PMID:24202394; http://dx.doi.org/10.1038/nm.3389
   PubMed Web of Science ®Google Scholar
• Merchant AA, Matsui W. Targeting Hedgehog–a cancer stem cell pathway. Clin Cancer Res 2010; 16:3130-40; PMID:20530699; http://dx.doi.org/10.1158/1078-0432.CCR-09-2846
   PubMed Web of Science ®Google Scholar
• Dierks C, Grbic J, Zirlik K, Beigi R, Englund NP, Guo GR, Veelken H, Engelhardt M, Mertelsmann R, Kelleher JF, et al. Essential role of stromally induced hedgehog signaling in B-cell malignancies. Nat Med 2007; 13:944-51; PMID:17632527; http://dx.doi.org/10.1038/nm1614
   PubMed Web of Science ®Google Scholar
• Low JA, de Sauvage FJ. Clinical experience with Hedgehog pathway inhibitors. J Clin Oncol 2010; 28:5321-6; PMID:21041712; http://dx.doi.org/10.1200/JCO.2010.27.9943
   PubMed Web of Science ®Google Scholar
• Mar BG, Amakye D, Aifantis I, Buonamici S. The controversial role of the Hedgehog pathway in normal and malignant hematopoiesis. Leukemia 2011; 25:1665-73; PMID:21660044; http://dx.doi.org/10.1038/leu.2011.143
   PubMed Web of Science ®Google Scholar
• Irvine DA, Copland M. Targeting hedgehog in hematologic malignancy. Blood 2012; 119:2196-204; PMID:22223823; http://dx.doi.org/10.1182/blood-2011-10-383752
   PubMed Web of Science ®Google Scholar
• Jagani Z, Dorsch M, Warmuth M. Hedgehog pathway activation in chronic myeloid leukemia. Cell Cycle 2010; 9:3449-56; PMID:20928937; http://dx.doi.org/10.4161/cc.9.17.12945
   PubMed Web of Science ®Google Scholar
• Hamad A, Sahli Z, El Sabban M, Mouteirik M, Nasr R. Emerging therapeutic strategies for targeting chronic myeloid leukemia stem cells. Stem Cells Int 2013; 2013:724360; PMID:23935640; http://dx.doi.org/10.1155/2013/724360
   PubMedGoogle Scholar
• Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, Spek CA. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene 2010; 29:6314-22; PMID:20802532; http://dx.doi.org/10.1038/onc.2010.375
   PubMed Web of Science ®Google Scholar
• Dierks C, Beigi R, Guo G-R, Zirlik K, Stegert MR, Manley P, Trussell C, Schmitt-Graeff A, Landwerlin K, Veelken H, et al. Expansion of Bcr-Abl-Positive Leukemic Stem Cells Is Dependent on Hedgehog Pathway Activation. Cancer Cell 2008; 14:238-49; PMID:18772113; http://dx.doi.org/10.1016/j.ccr.2008.08.003
   PubMed Web of Science ®Google Scholar
• Warzecha J, Bonke L, Koehl U, Munkelt D, Gottig S, Percic D, Arabmotlagh M, Kurth A. The hedgehog inhibitor cyclopamine induces apoptosis in leukemic cells in vitro. Leuk Lymphoma 2008; 49:2383-6; PMID:19052992; http://dx.doi.org/10.1080/10428190802510315
   PubMed Web of Science ®Google Scholar
• Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y, et al. Drug resistance is dramatically restored by hedgehog inhibitors in CD34+ leukemic cells. Cancer Sci 2009; 100:948-55; PMID:19245435; http://dx.doi.org/10.1111/j.1349-7006.2009.01111.x
   PubMed Web of Science ®Google Scholar
• Katagiri S, Tauchi T, Okabe S, Minami Y, Kimura S, Maekawa T, Naoe T, Ohyashiki K. Combination of ponatinib with Hedgehog antagonist vismodegib for therapy-resistant BCR-ABL1-positive leukemia. Clin Cancer Res 2013; 19:1422-32; PMID:23319824; http://dx.doi.org/10.1158/1078-0432.CCR-12-1777
   PubMed Web of Science ®Google Scholar
• Swampillai AL, Salomoni P, Short SC. The role of autophagy in clinical practice. Clin Oncol (R Coll Radiol) 2012; 24:387-95; PMID:22032864; http://dx.doi.org/10.1016/j.clon.2011.09.010
   PubMed Web of Science ®Google Scholar
• Shanware NP, Bray K, Abraham RT. The PI3K, metabolic, and autophagy networks: interactive partners in cellular health and disease. Annu Rev Pharmacol Toxicol 2013; 53:89-106; PMID:23294306; http://dx.doi.org/10.1146/annurev-pharmtox-010611-134717
   PubMed Web of Science ®Google Scholar
• Gewirtz DA. Cytoprotective and nonprotective autophagy in cancer therapy. Autophagy 2013; 9:1263-5; PMID:23800720; http://dx.doi.org/10.4161/auto.25233
   PubMed Web of Science ®Google Scholar
• Helgason GV, Karvela M, Holyoake TL. Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011; 118:2035-43; PMID:21693757; http://dx.doi.org/10.1182/blood-2011-01-330621
   PubMed Web of Science ®Google Scholar
• Mishima Y, Terui Y, Taniyama A, Kuniyoshi R, Takizawa T, Kimura S, Ozawa K, Hatake K. Autophagy and autophagic cell death are next targets for elimination of the resistance to tyrosine kinase inhibitors. Cancer Sci 2008; 99:2200-8; PMID:18823378; http://dx.doi.org/10.1111/j.1349-7006.2008.00932.x
   PubMed Web of Science ®Google Scholar
• Bellodi C, Lidonnici MR, Hamilton A, Helgason GV, Soliera AR, Ronchetti M, Galavotti S, Young KW, Selmi T, Yacobi R, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. J Clin Invest 2009; 119:1109-23; PMID:19363292; http://dx.doi.org/10.1172/JCI35660
   PubMed Web of Science ®Google Scholar
• Nencioni A, Cea M, Montecucco F, Longo VD, Patrone F, Carella AM, Holyoake TL, Helgason GV. Autophagy in blood cancers: biological role and therapeutic implications. Haematologica 2013; 98:1335-43; PMID:24006406; http://dx.doi.org/10.3324/haematol.2012.079061
   PubMed Web of Science ®Google Scholar
• Jimenez-Sanchez M, Menzies FM, Chang YY, Simecek N, Neufeld TP, Rubinsztein DC. The Hedgehog signalling pathway regulates autophagy. Nat Commun 2012; 3:1200; PMID:23149744; http://dx.doi.org/10.1038/ncomms2212
   PubMed Web of Science ®Google Scholar
• Wang Y, Han C, Lu L, Magliato S, Wu T. Hedgehog signaling pathway regulates autophagy in human hepatocellular carcinoma cells. Hepatology 2013; 58:995-1010; PMID:23504944; http://dx.doi.org/10.1002/hep.26394
   PubMed Web of Science ®Google Scholar
• Li H, Li J, Li Y, Singh P, Cao L, Xu LJ, Li D, Wang Y, Xie Z, Gui Y. Sonic hedgehog promotes autophagy of vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2012; 303:H1319-31; PMID:23023870; http://dx.doi.org/10.1152/ajpheart.00160.2012
   PubMed Web of Science ®Google Scholar
• Petralia RS, Schwartz CM, Wang YX, Kawamoto EM, Mattson MP, Yao PJ. Sonic hedgehog promotes autophagy in hippocampal neurons. Biol Open 2013; 2:499-504; PMID:23789099; http://dx.doi.org/10.1242/bio.20134275
   PubMedGoogle Scholar
• Sarkar FH, Li Y, Wang Z, Kong D. The role of nutraceuticals in the regulation of Wnt and Hedgehog signaling in cancer. Cancer and Metastasis Reviews 2010; 29:383-94; PMID:20711635; http://dx.doi.org/10.1007/s10555-010-9233-4
   PubMed Web of Science ®Google Scholar
• Clevers H. Wnt/β-Catenin Signaling in Development and Disease. Cell 2006; 127:469-80; PMID:17081971; http://dx.doi.org/10.1016/j.cell.2006.10.018
   PubMed Web of Science ®Google Scholar
• Sengupta A, Banerjee D, Chandra S, Banerji SK, Ghosh R, Roy R, Banerjee S. Deregulation and cross talk among Sonic hedgehog, Wnt, Hox and Notch signaling in chronic myeloid leukemia progression. Leukemia 2007; 21:949-55; PMID:17361218; http://dx.doi.org/10.1038/sj.leu.2404657
   PubMed Web of Science ®Google Scholar
• Zhao C, Blum J, Chen A, Kwon HY, Jung SH, Cook JM, Lagoo A, Reya T. Loss of β-Catenin Impairs the Renewal of Normal and CML Stem Cells In Vivo. Cancer Cell 2007; 12:528-41; PMID:18068630; http://dx.doi.org/10.1016/j.ccr.2007.11.003
   PubMed Web of Science ®Google Scholar
• Heidel Florian H, Bullinger L, Feng Z, Wang Z, Neff Tobias A, Stein L, Kalaitzidis D, Lane SW, Armstrong SA. Genetic and Pharmacologic Inhibition of β-Catenin Targets Imatinib-Resistant Leukemia Stem Cells in CML. Cell Stem Cell 2012; 10:412-24; PMID:22482506; http://dx.doi.org/10.1016/j.stem.2012.02.017
   PubMedGoogle Scholar
• O'Hare T. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML. Blood 2004; 104:2532-9; PMID:15256422; http://dx.doi.org/10.1182/blood-2004-05-1851
   PubMed Web of Science ®Google Scholar
• O'Hare T, Walters DK, Stoffregen EP, Jia T, Manley PW, Mestan J, Cowan-Jacob SW, Lee FY, Heinrich MC, Deininger MW, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res 2005; 65:4500-5; PMID:15930265; http://dx.doi.org/10.1158/0008-5472.CAN-05-0259
   PubMed Web of Science ®Google Scholar
• Yuan X, Zhang Y, Zhang H, Jin J, Li X, Liu H, Feng Z, Chen X. Activity of the potent dual Abl/Src tyrosine kinase inhibitor FB2 against Bcr-Abl positive cell lines in vitro and in vivo. Leuk Res 2011; 35:237-42; PMID:20739063; http://dx.doi.org/10.1016/j.leukres.2010.07.041
   PubMedGoogle Scholar
• Klionsky DJ, Abdalla FC, Abeliovich H, Abraham RT, Acevedo-Arozena A, Adeli K, Agholme L, Agnello M, Agostinis P, Aguirre-Ghiso JA, et al. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy 2012; 8:445-544; PMID:22966490; http://dx.doi.org/10.4161/auto.19496
   PubMed Web of Science ®Google Scholar
• Jung CH, Ro SH, Cao J, Otto NM, Kim DH. mTOR regulation of autophagy. FEBS Lett 2010; 584:1287-95; PMID:20083114; http://dx.doi.org/10.1016/j.febslet.2010.01.017
   PubMed Web of Science ®Google Scholar
• Ambjørn M, Ejlerskov P, Liu Y, Lees M, Jäättelä M, Issazadeh-Navikas S. IFNB1/interferon-β-induced autophagy in MCF-7 breast cancer cells counteracts its proapoptotic function. Autophagy 2013; 9:287-302; PMID:23221969; http://dx.doi.org/10.4161/auto.22831
   PubMed Web of Science ®Google Scholar
• Kawahara T, Kawaguchi-Ihara N, Okuhashi Y, Itoh M, Nara N, Tohda S. Cyclopamine and quercetin suppress the growth of leukemia and lymphoma cells. Anticancer Res 2009; 29:4629-32; PMID:20032413
   PubMed Web of Science ®Google Scholar
• Kim JE, Yoon S, Choi BR, Kim KP, Cho YH, Jung W, Kim DW, Oh S, Kim DE. Cleavage of BCR-ABL transcripts at the T315I point mutation by DNAzyme promotes apoptotic cell death in imatinib-resistant BCR-ABL leukemic cells. Leukemia 2013; 27:1650-8; PMID:23434731; http://dx.doi.org/10.1038/leu.2013.60
   PubMed Web of Science ®Google Scholar
• Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation. Clin Cancer Res 2009; 15:1686-97; PMID:19240172; http://dx.doi.org/10.1158/1078-0432.CCR-08-2141
   PubMed Web of Science ®Google Scholar
• Weiner LM, Lotze MT. Tumor-cell death, autophagy, and immunity. N Engl J Med 2012; 366:1156-8; PMID:22435376; http://dx.doi.org/10.1056/NEJMcibr1114526
   PubMed Web of Science ®Google Scholar
• Mizushima N, Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011; 147:728-41; PMID:22078875; http://dx.doi.org/10.1016/j.cell.2011.10.026
   PubMed Web of Science ®Google Scholar
• Choi AMK, Ryter SW, Levine B. Autophagy in human health and disease. N Engl J Med 2013; 368:651-62; PMID:23406030; http://dx.doi.org/10.1056/NEJMra1205406
   PubMed Web of Science ®Google Scholar
• Janku F, McConkey DJ, Hong DS, Kurzrock R. Autophagy as a target for anticancer therapy. Nat Rev Clin Oncol 2011; 8:528-39; PMID:21587219; http://dx.doi.org/10.1038/nrclinonc.2011.71
   PubMed Web of Science ®Google Scholar
• Rosenfeld MR, Ye X, Supko JG, Desideri S, Grossman SA, Brem S, Mikkelson T, Wang D, Chang YC, Hu J, et al. A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme. Autophagy 2014; 10:1359-68; PMID:24991840; http://dx.doi.org/10.4161/auto.28984
   PubMed Web of Science ®Google Scholar
• Rangwala R, Leone R, Chang YC, Fecher L, Schuchter L, Kramer A, Tan KS, Heitjan DF, Rodgers G, Gallagher M, et al. Phase I trial of hydroxychloroquine with dose-intense temozolomide in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1369-79; PMID:24991839; http://dx.doi.org/10.4161/auto.29118
   PubMed Web of Science ®Google Scholar
• Vogl DT, Stadtmauer EA, Tan KS, Heitjan DF, Davis LE, Pontiggia L, Rangwala R, Piao S, Chang YC, Scott EC, et al. Combined autophagy and proteasome inhibition: a phase 1 trial of hydroxychloroquine and bortezomib in patients with relapsed/refractory myeloma. Autophagy 2014; 10:1380-90; PMID:24991834; http://dx.doi.org/10.4161/auto.29264
   PubMed Web of Science ®Google Scholar
• Rangwala R, Chang YC, Hu J, Algazy KM, Evans TL, Fecher LA, Schuchter LM, Torigian DA, Panosian JT, Troxel AB, et al. Combined MTOR and autophagy inhibition: phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma. Autophagy 2014; 10:1391-402; PMID:24991838; http://dx.doi.org/10.4161/auto.29119
   PubMed Web of Science ®Google Scholar
• Mahalingam D, Mita M, Sarantopoulos J, Wood L, Amaravadi R, Davis LE, Mita AC, Curiel TJ, Espitia CM, Nawrocki ST, et al. Combined autophagy and HDAC inhibition: a phase I safety, tolerability, pharmacokinetic, and pharmacodynamic analysis of hydroxychloroquine in combination with the HDAC inhibitor vorinostat in patients with advanced solid tumors. Autophagy 2014; 10:1403-14; PMID:24991835; http://dx.doi.org/10.4161/auto.29231
   PubMed Web of Science ®Google Scholar
• Barnard RA, Wittenburg LA, Amaravadi RK, Gustafson DL, Thorburn A, Thamm DH. Phase I clinical trial and pharmacodynamic evaluation of combination hydroxychloroquine and doxorubicin treatment in pet dogs treated for spontaneously occurring lymphoma. Autophagy 2014; 10:1415-25; PMID:24991836; http://dx.doi.org/10.4161/auto.29165
   PubMed Web of Science ®Google Scholar
• Gao J, Graves S, Koch U, Liu S, Jankovic V, Buonamici S, El Andaloussi A, Nimer SD, Kee BL, Taichman R, et al. Hedgehog signaling is dispensable for adult hematopoietic stem cell function. Cell Stem Cell 2009; 4:548-58; PMID:19497283; http://dx.doi.org/10.1016/j.stem.2009.03.015
   PubMed Web of Science ®Google Scholar
• Hofmann I, Stover EH, Cullen DE, Mao J, Morgan KJ, Lee BH, Kharas MG, Miller PG, Cornejo MG, Okabe R, et al. Hedgehog signaling is dispensable for adult murine hematopoietic stem cell function and hematopoiesis. Cell Stem Cell 2009; 4:559-67; PMID:19497284; http://dx.doi.org/10.1016/j.stem.2009.03.016
   PubMed Web of Science ®Google Scholar
• Wang Y, Ding Q, Yen CJ, Xia W, Izzo JG, Lang JY, Li CW, Hsu JL, Miller SA, Wang X, et al. The crosstalk of mTOR/S6K1 and Hedgehog pathways. Cancer Cell 2012; 21:374-87; PMID:22439934; http://dx.doi.org/10.1016/j.ccr.2011.12.028
   PubMed Web of Science ®Google Scholar
• Goussetis DJ, Gounaris E, Wu EJ, Vakana E, Sharma B, Bogyo M, Altman JK, Platanias LC. Autophagic degradation of the BCR-ABL oncoprotein and generation of antileukemic responses by arsenic trioxide. Blood 2012; 120:3555-62; PMID:22898604; http://dx.doi.org/10.1182/blood-2012-01-402578
   PubMed Web of Science ®Google Scholar
• Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, Pan S, Dong X, Tan G, Wei Z. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Mol Cancer Ther 2014; 13:1589-98; PMID:24705351; http://dx.doi.org/10.1158/1535-7163.MCT-13-1043
   PubMed Web of Science ®Google Scholar
• Zeng X, Li Y, Fan J, Zhao H, Xian Z, Sun Y, Wang Z, Wang S, Zhang G, Ju D. Recombinant human arginase induced caspase-dependent apoptosis and autophagy in non-Hodgkin's lymphoma cells. Cell Death Dis 2013; 4:e840; PMID:24113174; http://dx.doi.org/10.1038/cddis.2013.359
   PubMedGoogle Scholar
• Li Y, Zhu H, Zeng X, Fan J, Qian X, Wang S, Wang Z, Sun Y, Wang X, Wang W, et al. Suppression of autophagy enhanced growth inhibition and apoptosis of interferon-beta in human glioma cells. Mol Neurobiol 2013; 47:1000-10; PMID:23329343; http://dx.doi.org/10.1007/s12035-013-8403-0
   PubMed Web of Science ®Google Scholar
• Fan J, Zeng X, Li Y, Wang S, Wang Z, Sun Y, Gao H, Zhang G, Feng M, Ju D, et al. Autophagy plays a critical role in ChLym-1-induced cytotoxicity of non-hodgkin's lymphoma cells. PLoS One 2013; 8:e72478; PMID:24015249; http://dx.doi.org/10.1371/journal.pone.0072478
   PubMedGoogle Scholar